Last $2.07 USD
Change Today -0.02 / -0.96%
Volume 30.6K
SNGX On Other Exchanges
Symbol
Exchange
Berlin
OTC BB
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

soligenix inc (SNGX) Snapshot

Open
$2.04
Previous Close
$2.09
Day High
$2.10
Day Low
$2.03
52 Week High
01/21/14 - $2.50
52 Week Low
06/24/13 - $0.86
Market Cap
41.1M
Average Volume 10 Days
21.9K
EPS TTM
$-0.62
Shares Outstanding
19.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOLIGENIX INC (SNGX)

Related News

No related news articles were found.

soligenix inc (SNGX) Related Businessweek News

No Related Businessweek News Found

soligenix inc (SNGX) Details

Soligenix, Inc., a development stage biopharmaceutical company, engages in developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. The company focuses on two segments, BioTherapeutics and Vaccine/Biodefense. The BioTherapeutics segment develops products for orphan diseases and areas of unmet medical need, such as oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and Graft-versus-Host disease. It is developing proprietary formulations of oral beclomethasone 17.21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease, acute radiation enteritis, and chronic Graft-versus-Host disease, as well as novel innate defense regulator technology for the treatment of oral mucositis. The Vaccine/Biodefense segment develops vaccines and therapeutics for military and civilian applications. Its lead biodefense products in development are a recombinant subunit vaccine, known as RiVax, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax, a vaccine against anthrax exposure. These vaccine programs are supported by the company’s heat stabilization technology, known as ThermoVax. This segment is also developing OrbeShield for the treatment of gastrointestinal acute radiation syndrome. The company was founded in 1987 and is headquartered in Princeton, New Jersey.

17 Employees
Last Reported Date: 04/8/14
Founded in 1987

soligenix inc (SNGX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $641.0K
Acting Chief Financial Officer, Principal Acc...
Total Annual Compensation: $276.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $244.0K
Compensation as of Fiscal Year 2013.

soligenix inc (SNGX) Key Developments

Soligenix, Inc. Reports Earnings Results for the Year Ended December 31, 2013

Soligenix, Inc. reported earnings results for the year ended December 31, 2013. For the year, the company's net loss was $10.1 million, or $0.65 per share, as compared to $4.2 million, or $0.37 per share, for the year ended December 31, 2013 and 2012, respectively. Included in the net loss for the year ended December 31, 2013 is a non-cash charge of $3.7 million, or $0.24 per share, due to the change in fair value of the liability related to warrants issued in the company's June 25, 2013 registered public offering as well as a $1.5 million non-cash charge related to the exclusive worldwide collaboration with Intrexon Corporation.

Soligenix, Inc. Presents at Noble Financial Capital Markets Tenth Annual Equity Conference, Jan-20-2014 02:30 PM

Soligenix, Inc. Presents at Noble Financial Capital Markets Tenth Annual Equity Conference, Jan-20-2014 02:30 PM. Venue: Club Med Sandpiper Bay Resort & Spa, Room One, 4500 SE Pine Valley Street, Port Saint Lucie, Florida, United States. Speakers: Christopher J. Schaber, Chairman, Chief Executive Officer and President.

Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax Vaccine Heat Stabilization Technology

Soligenix, Inc. announced significant steps forward in the development of ThermoVax(TM), its proprietary vaccine thermostabilization platform technology. Recent studies have demonstrated the potential for heat-sensitive vaccines formulated using this technology to withstand temperatures exceeding 40 degrees Celsius (104 degrees Fahrenheit) for up to one year. The underlying work has been conducted with the Company's proprietary ricin toxin vaccine (RiVax(TM)) as part of a continuing program to evaluate the effectiveness of protein subunit vaccines to withstand extremes of temperature and other environmental stress conditions. These studies amplify and extend former evaluations that indicated retention of potency for at least six months at temperatures as high as 40 degrees Celsius, outside the range of typical vaccine storage conditions. The research and development of ThermoVax(TM) is currently being supported by a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant to Soligenix for biodefense vaccines to prevent ricin toxin and anthrax exposure. These results underline the potential for long-term stability of subunit vaccines stored under ambient conditions or at high temperatures. Vaccines are almost always stored refrigerated because of vulnerability to heat exposure, resulting in loss of potency and efficacy. By employing ThermoVax(TM) during final formulation of RiVax(TM), which is extremely unstable in its liquid form, a stable and potent vaccine is produced that is capable of withstanding temperatures at least as high as 40 degrees Celsius for up to one year. The most recent studies, which employed a combination of sensitive techniques to evaluate the structure of the vaccine and the resulting immunogenicity, demonstrated that the vaccine retained original levels of potency after one year of storage at 40 degrees Celsius. RiVax(TM), formulated with ThermoVax(TM), has the potential to facilitate easier storage and distribution in a national stockpile for emergency situations. In addition to RiVax(TM), the Company has previously reported that its proprietary anthrax vaccine, VeloThrax(TM), formulated with ThermoVax(TM) and subsequently exposed to temperatures as high as 70 degrees Celsius (158 degrees Fahrenheit) for at least one month, retained full potency in animals as well as other characteristics such as receptor binding indicative of full structural integrity. The combination of ThermoVax(TM) and VeloThrax(TM) along with a potent secondary adjuvant resulted in rapid onset of antibodies correlated to protection against anthrax in animal models. Additional studies have confirmed longer term stability of VeloThrax(TM) at 40 degrees Celsius for up to four months.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNGX:US $2.07 USD -0.02

SNGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNGX.
View Industry Companies
 

Industry Analysis

SNGX

Industry Average

Valuation SNGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLIGENIX INC, please visit www.soligenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.